 |
|
|
| |
Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral regimens at baseline
|
| |
| |
Karam Mounzer1, Jihad Slim2, Moti Ramgopal3, Malcolm Hedgcock4, Mark Bloch5, Jorge Santana6, Ines Mendes7, Xu Zhang7, Peter Sklar7, Jairo M Montezuma-Rusca7, Sorana Segal-Maurer8
1Philadelphia FIGHT, Philadelphia, PA, USA; 2New York Medical College, Valhalla, NY, USA; 3Midway Immunology and Research Center, Fort Pierce, FL, USA; 4Spectrum Health, Vancouver, BC, Canada; 5Holdsworth House Medical Practice, Darlinghurst, NSW, Australia; 6University of Puerto Rico, San Juan, Puerto Rico; 7Gilead Sciences, Inc., Foster City, CA, USA; 8NewYork-Presbyterian Queens, Flushing, NY, USA
|
| |
|
|
|
|
|
